Merck and Amgen Boldly Test the Limits of Prescription Drug Price Increases
Pharmaceutical companies generally keep drug prices increases around 5% per year. This year, Merck and Amgen tested that unofficial limit. [...]
Cost-Effective Insulin Glargine Biosimilar Could Upend Reference Diabetes Drug; McKinsey Estimates Biosimilar Market Will Hit $30 Billion by 2025
The Food and Drug Administration (FDA) recently approved Semglee, an insulin glargine biosimilar product. Compared to reference drug Lantus, the [...]
Cigna Incentive Program Offers $500 to Switch from Biologics to Biosimilars, Drug Savings Could Reach $375 Billion
In an effort to promote biosimilars, Cigna is offering $500 if customers switch to a lower-cost offering. Experts project that [...]
Despite WHO Recommendation, COVID-19 Drug Too Costly and Inaccessible; Will Roche Give Up Monopoly?
The World Health Organization (WHO) has recommended the use of monoclonal antibody tocilizumab in cases of severe COVID-19 illness. However, [...]
Biosimilar Market to Hit $178 Billion in 2024
In 2006, the European Medicines Agency approved its first biosimilar. Omnitrope was developed in cases of growth hormone deficiency. Now, [...]
Xcenda Leader Provides Insight on Biosimilars for Payers and Pharma
Managing Director Allen Lising of Xcenda’s FormularyDecisions shared his thoughts on biosimilars. He notes that when it comes to the [...]
Article Examines Coverage of Biosimilars
A recent article published in JAMA examines how commercial health plans cover biosimilars compared to their reference products. While Congress [...]
Report: Biosimilars Drive Down Prices of Biologics
A recent study published in JAMA Network Open suggests biologics filgrastim, pegfilgrastim, infliximab and insulin glargine all saw their prices [...]